9-aminocamptothecin
- Generic Name
- 9-aminocamptothecin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H17N3O4
- CAS Number
- 91421-43-1
- Unique Ingredient Identifier
- 5MB77ICE2Q
- Background
Aminocamptothecin has been used in trials studying the treatment of Lymphoma, Gastric Cancer, Ovarian Cancer, Esophageal Cancer, and Ovarian Neoplasms, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Aminocamptothecin in Treating Patients With T-cell Lymphoma
- Conditions
- First Posted Date
- 2004-08-11
- Last Posted Date
- 2013-07-26
- Lead Sponsor
- Yale University
- Target Recruit Count
- 12
- Registration Number
- NCT00002635
- Locations
- ๐บ๐ธ
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
๐บ๐ธRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
๐บ๐ธNew England Medical Center Hospital, Boston, Massachusetts, United States
Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian Cancer
- Conditions
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2012-11-09
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT00002671
- Locations
- ๐บ๐ธ
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States
๐บ๐ธNew York Presbyterian Hospital - Cornell Campus, New York, New York, United States
๐บ๐ธOverlook Hospital, Summit, New Jersey, United States
Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma
- First Posted Date
- 2004-04-22
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT00002745
- Locations
- ๐บ๐ธ
St. Joseph's Hospital and Medical Center, Paterson, New Jersey, United States
๐บ๐ธCooper Cancer Institute, Camden, New Jersey, United States
๐บ๐ธWalter Reed Army Medical Center, Washington, District of Columbia, United States
Aminocamptothecin in Treating Patients With Stomach Cancer or Cancer of the Esophagus
- First Posted Date
- 2004-03-30
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 15
- Registration Number
- NCT00003192
- Locations
- ๐บ๐ธ
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
๐บ๐ธLouis A. Weiss Memorial Hospital, Chicago, Illinois, United States
๐บ๐ธOncology/Hematology Associates of Central Illinois, P.C., Peoria, Illinois, United States
A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00001427
- Locations
- ๐บ๐ธ
National Cancer Institute (NCI), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.